author-photo

Danni Yu

Eli Lilly and Company

13

Papers

113

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.

2021 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (4)
Blocking TIM-3 in Treatment-Refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (9)
Safety and antitumor activity of α-PD-L1 antibody as monotherapy or in combination with α-TIM-3 antibody in patients with microsatellite instability-high/mismatch repair-deficient tumors.

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (5)
Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.

2020 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (11)
A Phase 1 Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer

2019 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (20)
Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resistant prostate cancer (MCRPC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (8)
Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents

2018 Cancer Research
Show All
- Source
- Cite
- Save
Citations (1)
A phase I study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients (pts) with advanced solid tumors.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer

2016 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (38)